Veru (VERU) Receivables - Other (2011 - 2021)

Veru (VERU) posted quarterly Receivables - Other of $5.0 million for Q2 2021, up 100.0% quarter-over-quarter from $2.5 million in Q1 2021.

Veru (VERU) Receivables - Other (2011 - 2021) Analysis & Trends

Veru (VERU) has reported Receivables - Other for 7 consecutive years, with $5.0 million the latest figure, recorded in Q2 2021.

In Q2 2021, Receivables - Other changed N/A year-over-year to $5.0 million; the TTM figure through Jun 2021 stood at $5.0 million (changed N/A YoY), while the FY2017 annual figure was $100139.0, changed N/A from the prior year.
Receivables - Other improved to $5.0 million in Q2 2021 per VERU's latest filing, from $2.5 million in the prior quarter.
Across five years, Receivables - Other topped out at $5.0 million in Q2 2021 and bottomed at $100139.0 in Q3 2017.
Historically, Receivables - Other has averaged $1.5 million across 4 years, with a median of $128317.0 in 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.92 Bn	131.07 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.91 Bn	77.91 Bn	3.93 Bn
3	Argenx Se	64.87 Bn	59.68 Bn	1.37 Bn
4	Moderna	58.18 Bn	53.04 Bn	52.00 Mn
5	BeOne Medicines	41.96 Bn	36.87 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.53 Bn	28.23 Bn	992.69 Mn
7	BioNTech SE	27.79 Bn	9.40 Bn	668.28 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
9	Royalty Pharma	27.37 Bn	26.53 Bn	-
10	Veru	60.90 Mn	35.11 Mn	-

Download Data